Obesity and COPD: Associated Symptoms, Health-related Quality of Life, and Medication Use
Autor: | Laura M. Cecere, David J. Pierson, Alyson J. Littman, Edmunds M. Udris, David H. Au, Christopher G. Slatore, Chris L. Bryson, Edward J. Boyko |
---|---|
Rok vydání: | 2011 |
Předmět: |
Male
Washington Pulmonary and Respiratory Medicine medicine.medical_specialty Exacerbation Hospitals Veterans Cross-sectional study Population Overweight Article Body Mass Index Pulmonary Disease Chronic Obstructive Quality of life Surveys and Questionnaires Internal medicine Administration Inhalation Humans Medicine Obesity education Aged Physician-Patient Relations education.field_of_study COPD business.industry Smoking medicine.disease Bronchodilator Agents Respiratory Function Tests respiratory tract diseases Cross-Sectional Studies Dyspnea Quality of Life Physical therapy Regression Analysis Female medicine.symptom business Body mass index |
Zdroj: | COPD: Journal of Chronic Obstructive Pulmonary Disease. 8:275-284 |
ISSN: | 1541-2563 1541-2555 |
Popis: | There is little data about the combined effects of COPD and obesity. We compared dyspnea, health-related quality of life (HRQoL), exacerbations, and inhaled medication use among patients who are overweight and obese to those of normal weight with COPD.We performed secondary data analysis on 364 Veterans with COPD. We categorized subjects by body mass index (BMI). We assessed dyspnea using the Medical Research Council (MRC) dyspnea scale and HRQoL using the St. George's Respiratory Questionnaire. We identified treatment for an exacerbation and inhaled medication use in the past year. We used multiple logistic and linear regression models as appropriate, with adjustment for age, COPD severity, smoking status, and co-morbidities.The majority of our population was male (n = 355, 98%) and either overweight (n = 115, 32%) or obese (n = 138, 38%). Obese and overweight subjects had better lung function (obese: mean FEV(1) 55.4% ±19.9% predicted, overweight: mean FEV(1) 50.0% ±20.4% predicted) than normal weight subjects (mean FEV(1) 44.2% ±19.4% predicted), yet obese subjects reported increased dyspnea [adjusted OR of MRC score ≥2 = 4.91 (95% CI 1.80, 13.39], poorer HRQoL, and were prescribed more inhaled medications than normal weight subjects. There was no difference in any outcome between overweight and normal weight patients.Despite having less severe lung disease, obese patients reported increased dyspnea and poorer HRQoL than normal weight patients. The greater number of inhaled medications prescribed for obese patients may represent overuse. Obese patients with COPD likely need alternative strategies for symptom control in addition to those currently recommended. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |